West Pharmaceutical Services Strengthens Support for China’s Biologics Ecosystem with Integrated Prefillable Syringe System Launch at CPHI China 2026

The West Synchrony™ Prefillable Syringe (PFS) System offers strategic infrastructure to support Chinese biotech innovators to expand their global footprint in biologics and vaccines.

SHANGHAI, CHINA - Media OutReach Newswire - 16 June 2026 - West Pharmaceutical Services, Inc. (NYSE: WST), a long-standing partner to China's pharmaceutical industry, today announced the availability of its West Synchrony™ prefillable syringe (PFS) system to drug developers at CPHI & PMEC China 2026, taking place June 16-18, 2026. This innovative platform uniquely integrates the syringe barrel, plunger, and needle shield/tip cap into a fully harmonized, verified system from a single supplier and emphasizes the company's commitment to supporting the development of China's biopharmaceutical sector in alignment with the country's 15th Five-Year Plan. By strengthening the innovation ecosystem and accelerating development and time to market, the company supports China's biopharmaceutical companies in achieving biotechnology breakthroughs and reaching global milestones.

Enabling China's Next Phase of Global Biopharmaceutical Growth

China's biopharmaceutical sector is entering a new phase of global relevance. Long recognized as a strategic pillar of the national economy, sustained policy support and investment over the past decade have helped build deep scientific capabilities and a rapidly maturing innovation ecosystem. As more biopharmaceutical companies "Go Global", many are establishing a growing international footprint, while others are accelerating their overseas ambitions. Emerging as core players on the global stage, Chinese companies accounted for nearly 50%¹ of all new drug molecules entering human trials in the first half of 2025 alone. At the same time, the growing complexity of biologics and vaccines is driving increased demand for advanced, high-quality drug delivery and packaging systems that can support product performance and safety from early development through commercialization. Competing globally also requires navigating stringent regulatory environments while ensuring reliable, scalable supply. Together, these factors make trusted partners with proven technical expertise and international regulatory experience critical for sustainable growth. To support Chinese biopharmaceutical companies in their ambitions, West has now made the West Synchrony™ PFS system available in the country.

West Synchrony™ PFS System

This gives Chinese innovators the infrastructure needed to compete on quality, safety, and regulatory compliance across international markets, with greater confidence and efficiency. "Chinese biopharmaceutical companies today have established themselves as serious global innovators, with significant opportunities to sustain momentum through high‑quality innovation," said Maha Guruswamy, Vice President & Managing Director, Commercial, Asia Pacific. "The challenge is that a traditional, individual-component system introduces significant technical and regulatory complexities. West Synchrony addresses these by providing a fully verified and integrated containment and delivery system from a single source, allowing our partners to accelerate development and focus on delivering therapies to patients."

Deepening A Long-Term Partnership with China's Pharmaceutical Ecosystem

The introduction of the West Synchrony™ PFS system reflects the company's decades-long commitment to supporting pharmaceutical innovation. This investment extends beyond product offerings to include technical expertise, regulatory support, and a single source of accountability that serve both domestic Chinese companies and multinational partners operating in China. "As China's biopharmaceutical companies continue to strengthen their capabilities and expand their presence globally, West is committed to partnering with them at every stage of their growth journey," said Philip Wang, Senior Director, Commercial, China. "We aim to enable them to achieve their global ambitions, and the West Synchrony™ PFS system is one example from our portfolio of high‑quality, innovative solutions that provide customers with the same trusted infrastructure relied upon by leading multinational pharmaceutical companies worldwide."

Join West at CPHI & PMEC China 2026

The West Synchrony™ PFS system will be showcased at CPHI & PMEC China 2026, where an expert from West will present on the role of integrated delivery systems in supporting China's next phase of biopharmaceutical innovation and its global ambitions for expansion. Trade media and industry stakeholders interested in learning more about the technology and its application in biologics are invited to visit the West booth during the exhibition. The details of the presentation are as follows:

Presentation: "Stop Piecing It Together—Get an Integrated Verified Prefillable Syringe System from One Source"

• Date & Time: June 17, 14:10-14:40

• Location: Shanghai New International Expo Center

• Speaker: Lynn Yao, Senior Manager, TCS, AP

The West Synchrony™ PFS System is now available to bio and pharmaceutical companies in China. Visit West at Booth N5D18 to learn more, or find out more information via the website here.

Forward-Looking Statements

Certain forward-looking statements are included in this press release. They use words and phrases such as "achieving biotechnology breakthroughs," "reaching global milestones," "accelerate development," and other similar terminology. These statements include, but are not limited to, statements regarding the anticipated benefits of the West Synchrony™ prefillable syringe system in China, the expected growth of China's bio-health and pharmaceutical industries, and West's ability to support customers' development and commercialization efforts. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in market conditions, regulatory requirements, global economic and geopolitical conditions, customer demand, supply chain constraints, competitive developments, technological changes, and other risks. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year that ended on December 31, 2025. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

¹ Goldman Sachs, "China Is Increasing Its Share of Global Drug Development", December 2025. https://www.goldmansachs.com/insights/articles/china-is-increasing-its-share-of-global-drug-development

Hashtag: #WestPharmaceuticalServices

The issuer is solely responsible for the content of this announcement.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support its customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, USA, West in its fiscal year 2025 generated USD 3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries in the United States and other jurisdictions, unless otherwise noted.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

West Pharmaceutical Services, Booth N5D18, CPHI & PMEC China 2026

HONG KONG SAR - Media OutReach Newswire - 19 June 2026 - The 2026 International Automotive and Supply Chain Expo (Hong Kong) officially opened today. Under the theme "Luxury, Elevated to a New Realm", ZEEKR unveiled the global expansion strategy for its dual flagship 9-Series models — the ZEEKR 9X and ZEEKR 009 Grand.

ZEEKR Surpasses 800,000 Global Deliveries and Unveils Global Expansion Strategy for Dual Flagship 9-Series Models

As a key gateway connecting China with global markets, Hong Kong serves as an important benchmark for the premium automotive industry and a strategic platform for luxury brands expanding internationally. Launching the global strategy for the 9-Series in Hong Kong marks a significant new chapter in ZEEKR's growth across the global premium new energy vehicle market.

800,000 Deliveries Milestone Underscores ZEEKR's Global Growth Momentum

Strong market performance continues to support ZEEKR's expansion in the global premium new energy vehicle segment. As of June 16, 2026, ZEEKR's cumulative global deliveries officially exceeded 800,000 vehicles, marking a major milestone for the brand.

In Hong Kong, ZEEKR has maintained strong momentum. From January to May 2026, ZEEKR captured a 40.7% market share of Hong Kong's luxury vehicle segment, ranking first among all luxury automotive brands. The ZEEKR 009 ranked as Hong Kong's best-selling luxury MPV, while the ZEEKR 7X became the city's best-selling luxury SUV.

Across key international markets, ZEEKR continues to achieve strong results. In Thailand, the brand was the best-selling luxury pure-electric MPV brand in 2025 and retained its leadership position from January to May 2026. In Malaysia, ZEEKR ranked No.1 among luxury pure-electric brands during the same period, with the ZEEKR 7X leading the luxury electric SUV category and the ZEEKR 009 remaining the top-selling luxury electric MPV. In Australia, ZEEKR continued to lead the luxury SUV segment priced above AUD 65,000 from January to May. In Mexico, the ZEEKR 7X secured the monthly luxury EV sales title in both April and May.

Dual Flagship 9-Series Models Showcase ZEEKR's Technology-Luxury Vision

At this year's expo, ZEEKR is showcasing five models spanning family mobility, executive transportation and flagship luxury, highlighting the breadth of its premium product portfolio.

The ZEEKR 9X, ZEEKR's new global flagship of ultra-luxury SUV, is built on the SEA-S architecture and features a 900V high-performance silicon carbide electric drive system delivering more than 1,030 kW of maximum power. Four integrated safety structures combined with extensive use of 2,000 MPa ultra-high-strength steel contribute to a torsional rigidity rating of 41,600 N·m/deg, setting a new benchmark for safety in the hybrid SUV segment. The ZEEKR 9X recently opened pre-sales in the Middle East, where it has received strong market interest. The model is scheduled to expand into key markets across Latin America, Central Asia and Europe.

The ZEEKR 009 Grand, the brand's global ultra-luxury four-seater flagship MPV, features a 720-degree comprehensive safety architecture and the world's first integrated die-cast C-ring cabin structure, delivering segment-leading rear-seat protection. The second row is equipped with two ultra-soft aniline leather executive seats featuring 20 massage points and an industry-leading seven-zone graphene heating system, creating an exceptional luxury experience for rear passengers. The right-hand-drive version of the ZEEKR 009 Grand is scheduled to launch in Hong Kong in the fourth quarter of 2026.

The ZEEKR 8X, a super hybrid high-performance flagship SUV, also makes its Hong Kong debut. Built on the SEA-S Super Hybrid Architecture, the ZEEKR 8X delivers a flagship experience across four key dimensions: performance, intelligence, safety and comfort.

ZEEKR Surpasses 800,000 Global Deliveries and Unveils Global Expansion Strategy for Dual Flagship 9-Series Models

Expanding Global Capabilities and Opening a New Chapter of Technology Luxury

As its product lineup continues to grow and its international footprint expands, ZEEKR is accelerating the development of a comprehensive global operating system spanning R&D, product planning, market operations and customer services. Today, ZEEKR's overseas business covers more than 60 major cities worldwide with a rapidly growing global user base.

As the global automotive industry accelerates toward electrification and intelligent mobility, the luxury vehicle market is entering a new era in which technological innovation is redefining the premium experience. Leveraging Hong Kong's position as a globally connected international hub, ZEEKR will continue to deepen its global presence and advance the evolution of luxury through innovation. Through cutting-edge technologies, exceptional products and comprehensive lifecycle services, ZEEKR is committed to delivering a distinctive technology-luxury mobility experience for customers around the world.

Hashtag: #ZEEKR

The issuer is solely responsible for the content of this announcement.

About Zeekr

Zeekr is the global luxury electric vehicle technology brand from Geely Auto Group. Utilizing advanced software-defined architectures and cutting-edge propulsion technologies, Zeekr is dedicated to creating a fully integrated user ecosystem with innovation at its core.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **